アフェレーシスの世界市場：血漿交換、血小板フェレーシス、赤血球アフェレーシス、白血球除去療法、循環光療法...市場調査レポートについてご紹介

1 Introduction (Page No. – 16)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 20)
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Estimation
2.5 Assumptions for the Study

3 Executive Summary (Page No. – 27)

4 Premium Insights (Page No. – 32)
4.1 Growth Potential of the Apheresis Market
4.2 Asia-Pacific: Apheresis Market, By Application (2014)
4.3 U.S. Apheresis Market, By Product Type
4.4 Apheresis Market: Regional Mix
4.5 Apheresis Market: Developed vs Developing Countries

5 Market Overview (Page No. – 36)
5.1 Introduction
5.2 Market Segmentation
5.2.1 By Product Type
5.2.2 By Procedure
5.2.3 By Technology
5.2.4 By Application
5.3 Market Dynamics
5.3.1 Market Drivers
5.3.1.1 Rising Prevalence of Various Diseases and Related Increase in Disability Adjusted Life Years (DALYS)
5.3.1.2 Increasing Demand for Source Plasma From Biopharmaceutical Companies and Corresponding Increase in Source Plasma Collections
5.3.1.3 Severity of Blood Shortage and Growing Concerns Regarding Blood Safety
5.3.2 Market Restraints
5.3.2.1 High Cost of Apheresis Devices and Procedures
5.3.2.2 Scarcity of Qualified Donors
5.3.3 Market Opportunities
5.3.3.1 Extending Reach of Apheresis in the Untapped Pediatric Segment
5.3.3.2 Emerging Economies With Increasing Investments From Government Bodies and Leading Players
5.3.4 Market Challenges
5.3.4.1 Lack of Awareness and Challenges in Donor Recruitment

6 Industry Insights (Page No. – 47)
6.1 Introduction
6.2 Industry Trends
6.2.1 Growing Number of Agreements and Partnerships
6.3 Porter’s Five Force Analysis
6.3.1 Threat of New Entrants
6.3.2 Threat of Substitutes
6.3.3 Bargaining Power of Suppliers
6.3.4 Bargaining Power of Buyers
6.3.5 Intensity of Competitive Rivalry
6.4 Regulatory Analysis
6.4.1 North America
6.4.1.1 U.S.
6.4.1.2 Canada
6.4.2 Europe
6.4.3 Asia-Pacific
6.4.3.1 Japan
6.4.3.2 China
6.4.3.3 India

7 Global Apheresis Market, By Procedure (Page No. – 55)
7.1 Introduction
7.2 Automated/Apheresis Blood Collection
7.3 Therapeutic Apheresis
7.3.1 Therapeutic Apheresis Market, By Disease
7.3.1.1 Neurological Disorders
7.3.1.2 Blood Disorders
7.3.1.3 Cardiovascular Disorders
7.3.1.4 Renal Disorders
7.3.1.5 Autoimmune Disorders
7.3.1.6 Metabolic Disorders
7.3.1.7 Other Disorders
7.3.2 Therapeutic Apheresis Market, By Procedure
7.3.2.1 Therapeutic Plasma Exchange (TPE)
7.3.2.2 Therapeutic Cytapheresis
7.3.2.2.1 Therapeutic Erythrocytapheresis
7.3.2.2.2 Therapeutic Plateletphersis
7.3.2.2.3 Leukapheresis
7.3.2.3 Photopheresis
7.3.2.4 Extracorporeal Immunoadsorption (ECI)
7.3.2.5 Low-Density Lipoprotein (LDL) Apheresis

8 Global Apheresis Market, By Product (Page No. – 81)
8.1 Introduction
8.2 Devices
8.3 Disposables

9 Global Apheresis Market, By Technology (Page No. – 88)
9.1 Introduction
9.2 Centrifugation
9.2.1 Intermittent Flow
9.2.2 Continuous Flow
9.3 Membrane Separation

10 Global Apheresis Market, By Application (Page No. – 97)
10.1 Introduction
10.2 Plasmapheresis
10.3 Plateletpheresis
10.4 Erythrocytapheresis
10.5 Leukapheresis
10.6 Low Density Lipoprotein (LDL) Apheresis
10.7 Other Applications

11 Geographic Analysis (Page No. – 108)
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 France
11.3.3 U.K.
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest of Europe (RoE)
11.4 Asia-Pacific (APAC)
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Rest of Asia-Pacific
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest of Latin America (RoLA)
11.6 Middle East and Africa

12 Competitive Landscape (Page No. – 150)
12.1 Overview
12.2 Market Share Analysis
12.3 Competitive Situation and Trends
12.4 Agreements, Partnerships, and Collaborations
12.5 Mergers and Acquisitions
12.6 Expansion
12.7 New Product Launches

13 Company Profiles (Page No. – 158)
13.1 Introduction
13.2 Terumo Bct, Inc.
13.2.1 Business Overview
13.2.2 Products Offered
13.2.3 Recent Developments
13.2.4 MnM View
13.3 Asahi Kasei Medical Co., Ltd. (A Subsidiary of Asahi Kasei Group)
13.3.1 Business Overview
13.3.2 Products Offered
13.3.3 Recent Developments
13.3.4 MnM View
13.4 Fresenius Se & Co. KGAA
13.4.1 Business Overview
13.4.2 Products Offered
13.4.3 Recent Developments
13.4.4 MnM View
13.5 Haemonetics Corporation
13.5.1 Business Overview
13.5.2 Products Offered
13.5.3 Recent Developments
13.5.4 MnM View
13.6 Cerus Corporation
13.6.1 Business Overview
13.6.2 Products Offered
13.6.3 Recent Developments
13.6.4 MnM View
13.7 B. Braun Melsungen AG
13.7.1 Business Overview
13.7.2 Products Offered
13.7.3 Recent Developments
13.8 Hemacare Corporation
13.8.1 Business Overview
13.8.2 Company Snapshot: Hemacare Corporation
13.8.3 Services Offered
13.8.4 Recent Developments
13.9 Medica S.P.A
13.9.1 Business Overview
13.9.2 Products Offered
13.9.3 Recent Developments
13.10 Kawasumi Laboratories Inc.
13.10.1 Business Overview
13.10.2 Products Offered
13.10.3 Recent Developments
13.11 Kaneka Corporation
13.11.1 Business Overview
13.11.2 Products Offered
13.11.3 Recent Developments
13.12 Nikkiso Co., Ltd.
13.12.1 Business Overview
13.12.2 Products Offered
13.12.3 Recent Developments
13.13 Therakos, Inc.
13.13.1 Business Overview
13.13.2 Products Offered
13.13.3 Recent Developments

14 Appendix (Page No. – 184)
14.1 Insights of Industry Experts
14.2 Discussion Guide
14.3 Other Developments, 2011–2015
14.4 Introducing RT: Real-Time Market Intelligence
14.5 Available Customizations
14.6 Related Reports